EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow EYPT
EyePoint, Inc. (EYPT) EV/Sales
As of 16 October 2026, EyePoint, Inc. (EYPT) trades at a EV/Sales of 40.8×. Over the past ten years it has ranged from −0.7× (December 2022) to 408× (July 2026); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 34.0× | 1,669.42% |
| FY2024 | 1.9× | (84.74%) |
| FY2023 | 12.6× | 1,559.60% |
| FY2022 | 0.8× | (84.23%) |
| FY2021 | 4.8× | 111.90% |
| FY2020 | 2.3× | (75.29%) |
| FY2019 | 9.2× | (75.41%) |
| FY2018 | 37.4× | 17.36% |
| FY2018 | 31.8× | 586.42% |
| FY2017 | 4.6× | (20.64%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 392× | 223.86% |
| Mar 2026 | 121× | 255.55% |
| Dec 2025 | 34.0× | 73.52% |
| Sep 2025 | 19.6× | 132.80% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 1.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| PRLD Prelude Therapeutics Incorporated compare | 7.5× |
| XFOR X4 Pharmaceuticals, Inc. compare | 12.4× |
| OCGN Ocugen, Inc. compare | 36.2× |
| EYPT EyePoint, Inc. | 40.8× |
| PALI Palisade Bio, Inc. compare | 230× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)